| HOME >> BIOLOGY >> TECHNOLOGY |
Loss from operations (19,155) (13,820)
Interest and other income, net 1,080 1,057
Interest expense (291) (235)
Loss before noncontrolling
interest in Symphony Allegro, Inc. (18,366) (12,998)
Loss attributed to noncontrolling
interest in Symphony Allegro, Inc. 3,757 2,082
Net loss $(14,609) $(10,916)
Basic and diluted net loss per share $(0.47) $(0.46)
Shares used to compute
basic and diluted net loss per share 31,225 23,869
Alexza Pharmaceuticals, Inc.
(a development stage enterprise)
Condensed Consolidated Balance Sheets
(in thousands)
March 31, December 31,
2008 2007
Assets Unaudited (1)
Cash, cash equivalents and marketable
securities $75,716 69,391
Investments held by Symphony Allegro, Inc. 35,936 39,449
Other current assets 2,350 13,432
Total current assets 114,002 122,272
Property and equipment, net 25,999 26,156
Other non-current assets 694 697
Total assets 140,695 149,125
Liabilities and stockholders' equity
Current liabilities 15,741 16,180
Non-current liabilities
'/>"/>
| SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |